
Oncology NEWS International
- Oncology NEWS International Vol 5 No 7
- Volume 5
- Issue 7
Hycamtin Approved For Ovarian Cancer
PHILADELPHIA--SmithKline Beecham's Hycamtin (topotecan) has received marketing clearance from the FDA for the treatment of patients with metastatic ovarian cancer after failure of initial or subsequent chemotherapy. It is the first topoisomerase I inhibitor approved for use in the United States.
PHILADELPHIA--SmithKline Beecham's Hycamtin (topotecan) has receivedmarketing clearance from the FDA for the treatment of patientswith metastatic ovarian cancer after failure of initial or subsequentchemotherapy. It is the first topoisomerase I inhibitor approvedfor use in the United States.
Hycamtin is currently available in pharmacies and will receiveits official launch by SmithKline shortly. (Look for a New Productreport next month).
The approval was based in part on results from an open, randomizedcomparative study showing that patients treated with Hycamtinhad a significantly longer progression-free survival than patientstreated with paclitaxel (Taxol) and a numerically superior responserate.
[For a more detailed discussion of the pivotal trials, see OncologyNews International, May, 1996,"Panel Recommende HycamtinApproval for Ovarian Cancer".]
Articles in this issue
almost 30 years ago
Princess Diana Helps Raise Over $1 Million for Cancer Researchalmost 30 years ago
Study Gives Terminal Patients Option: $18,000 or More Treatmentalmost 30 years ago
Proven: Colorectal Screening Cuts Deaths 50%almost 30 years ago
Virtual Colonoscopy Technique Feasible in Detecting Polypsalmost 30 years ago
Trimetrexate Appears Beneficial in Colorectal Canceralmost 30 years ago
FDA Liaison Program Answers Patients' Questions About Trialsalmost 30 years ago
New Company Joins With RPR To Develop Intrabody Technologyalmost 30 years ago
More Insurers Covering ABMT, Despite Lack of Efficacy Dataalmost 30 years ago
CDC Says Teen Smoking Still RisingNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.





















































